Info

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders. The Company has one marketed product, Soliris (eculizumab), which is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In June 2007, the European Commission (E.C.) approved the use of Soliris for patients with PNH in the European Union, which also serves as the basis for approval in Iceland and Norway. Alexion has focused its product development programs on anti-inflammatory therapeutics for diseases. As of December 31, 2006, Alexion terminated operations at Antibody Technologies, Inc. (AAT) and relocated Combinatorial Human Antibody Library Technologies (CoALT) and other AAT technologies to its research and discovery groups in the Company’s Cheshire, Connecticut headquarters.(Source: 10-K)